Home BIA Management System in Patients With Heart Failure

Sponsor
Korea University Guro Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT05177081
Collaborator
Soonchunhyang University Hospital (Other)
40
2
2
15.3
20
1.3

Study Details

Study Description

Brief Summary

This study is a prospective, multi-center, open label, randomized clinical trial conducted in the republic of Korea. The objective of this study is to evaluate the efficacy and safety of the treatment using home bioelectrical impedance analysis (BIA) and linked application system in patients with heart failure (HF).

Condition or Disease Intervention/Treatment Phase
  • Device: Preemptive management using home BIA monitoring system
N/A

Detailed Description

The prevalence of HF is generally estimated at 1% to 2% of the general population. The more concerning thing is that HF patients are rapidly increasing due to an increase of elderly population derived from life extension; an increase in the number of survivors of heart disease due to the development of medical technology; and an increase in risk factors for HF such as obesity, diabetes, and ischemic heart disease.

HF is known that a quarter of HF patients are readmitted within 1 year, and the mortality rate within 5 years is about 50%. HF is a chronic condition, punctuated by acute decompensated episodes. Each acute decompensated event results in further organ damage: myocardial and renal damage occurring during such episodes may contribute to progressive left ventricular and/or renal dysfunction. Increasing frequency of acute events with disease progression leads to higher rates of hospitalization and increased risk of mortality.

The main symptoms of HF are shortness of breath and swelling, which are the main reasons for visiting the emergency room and hospitalization. After discharge, body water monitoring and management of HF patients are very important to prevent HF aggravation and re-hospitalization.

There are several methods of body fluid monitoring in HF patients. Current guidelines of heart failure recommends monitoring of pulmonary artery pressures using a wireless implantable hemodynamic monitoring system in symptomatic HF patients with previous HF hospitalization. Multi-parameter monitoring based on ICD is also recommended in order to improve clinical outcomes in HF patients. However, existing HF monitoring and management systems have limitations of its invasiveness, expensive costs and a lot of medical providers' efforts. Other body water monitoring methods are signs and symptoms monitoring and body weight-based monitoring. However, signs such as weight gain and edema or symptoms like dyspnea due to worsening heart failure were not recognized until just 7 and 3 days before the hospitalization event.

BIA, Bioelectrical impedance analysis can be a novel option for body water monitoring method in HF patients. Nowadays, it is possible to obtain more accurate body water by reflecting both intracellular and extracellular water by using multiple frequencies, and it is possible to accurately measure body water even in patients with unusual body water conditions such as heart failure status. Moreover, the changes of Bioelectrical Impedance are detected about two weeks before heart failure hospitalization. It is the key benefit for congestion monitoring and management.

Previous studies have shown that monitoring body water through non-invasive bioelectrical impedance can predict the worsening of HF even in patients with heart failure. In addition, there are studies that reported improvement of clinical results during treatment based on the edema index (extracellular water / total body water) during body water monitoring through non-invasive bioelectrical impedance.

Home BIA monitoring using BWA-ON has potential benefit for continuous water monitoring for edema control in patients with HF. Therefore, we aim to evaluate feasibility of treatment using home BIA and linked application system in patients with heart failure.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
40 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
multi-center, open label, randomized trialmulti-center, open label, randomized trial
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
Feasibility of Treatment Using Home Bioelectrical Impedance Analysis and Linked Application System in Patients With Heart Failure: A Multicenter Study
Actual Study Start Date :
Aug 23, 2021
Anticipated Primary Completion Date :
Dec 1, 2022
Anticipated Study Completion Date :
Dec 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Home BIA Monitoring group

Preemptive management by Body fluid monitoring system (BWA ON + App + Web)

Device: Preemptive management using home BIA monitoring system
Patients check their body composition and fluid using Home BIA system. Investigators analyze patients' body congestion status and send patient's edema status and direction of extra-diuretics usage to enrolled patients every one week.

No Intervention: Control group

Usual heart failure management (Outpatient follow-up and medical treatment)

Outcome Measures

Primary Outcome Measures

  1. Change from baseline in NT-proBNP [3 months]

    NT-proBNP

Secondary Outcome Measures

  1. Rate of heart failure hospitalizations (HHF) [3 months]

    Hospitalization for heart failure

  2. Change from baseline in edema index using BIA [3 months]

    Edema index by BIA

  3. Change from baseline in Creatinine [3 months]

    Creatinine

  4. Change from baseline in symptom of dyspnea [3 months]

    NYHA classification and VAS scale of dyspnea

Eligibility Criteria

Criteria

Ages Eligible for Study:
20 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Patients diagnosed heart failure

  2. Patients taking loop diuretics for HF symptom control

  3. Patients who can use a smart-phone

Exclusion Criteria:
  1. Patients with implanted devices that could interfere with the BIA such as ICD and CRT

  2. Patients with limb defects

  3. Patients who unable to stand alone

  4. Patients who are pregnant

  5. Patients with End-stage renal disease (ESRD) on hemodialysis, serum creatinine of more than 5mg/dL, or nephritic syndrome

  6. Patients with systemic diseases such as hypothyroidism, decompensated liver cirrhosis, and systemic lupus erythematosus.

  7. Patients with active cellulitis, severe varicose vein, deep vein thrombosis or lymphedema

Contacts and Locations

Locations

Site City State Country Postal Code
1 Soonchunhyang University Bucheon Hospital Bucheon-si Gyeonggi-do Korea, Republic of 14584
2 Korea University Guro Hospital Seoul Korea, Republic of 08308

Sponsors and Collaborators

  • Korea University Guro Hospital
  • Soonchunhyang University Hospital

Investigators

  • Principal Investigator: Eung Ju Kim, MD, PhD, Korea University Guro Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Eung Ju Kim, Professor, Korea University Guro Hospital
ClinicalTrials.gov Identifier:
NCT05177081
Other Study ID Numbers:
  • BWA ON Pilot
First Posted:
Jan 4, 2022
Last Update Posted:
Jan 4, 2022
Last Verified:
Jan 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by Eung Ju Kim, Professor, Korea University Guro Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 4, 2022